Sometimes—but not reliably for everyone. Randomized trials suggest that physiologic-dose systemic testosterone can provide a modest average improvement in sexual desire and sexual distress for some postmenopausal women with persistent low desire that causes personal distress, often described as hypoactive sexual desire disorder (HSDD). It is not a universal libido enhancer, and neither a low-desire complaint nor a “low” testosterone result can show that testosterone is the cause.
Sexual desire can shift with menopause symptoms, vaginal dryness or pain, sleep, stress, mood, physical health, medicines, alcohol or substance use, relationship context, and ordinary variation in how desire develops. For some people, desire is responsive: it may emerge after closeness, touch, or stimulation rather than appearing spontaneously beforehand. That pattern is not automatically a problem.
The short answer: testosterone may help in a specific clinical context
The strongest evidence for testosterone therapy for women concerns postmenopausal women with HSDD or similarly defined distressing low desire. The 2019 Global Consensus Position Statement on testosterone therapy for women identifies HSDD as the only evidence-based indication for testosterone therapy in women. It does not support testosterone for general wellbeing, fatigue, brain fog, mood, weight change, muscle gain, cognition, or disease prevention.
What the trials found: modest average benefit, not a universal libido boost
A 2019 systematic review and meta-analysis of 36 randomized trials involving 8,480 women (Islam and colleagues, Lancet Diabetes & Endocrinology) found improvements in sexual-function outcomes and sexual distress among postmenopausal women receiving testosterone compared with placebo or a comparator. The average difference was about 0.85 additional satisfying sexual events per month. This is an average across study participants, not a forecast of what any one person will experience.
“Additional satisfying sexual events” is also only one outcome. It does not mean testosterone resolves sexual pain, relationship strain, exhaustion, lack of privacy, low mood, medication effects, or every aspect of sexual wellbeing. Some individuals may notice little or no benefit, while others may not be appropriate candidates for hormone treatment in the first place.
The evidence mostly concerns postmenopausal women with distressing low desire
Research findings should not be broadly transferred to premenopausal women, postpartum women, people taking hormonal contraception, or people with premature ovarian insufficiency. The international consensus statement concludes that evidence is insufficient to recommend testosterone for sexual-function treatment in premenopausal women.
Low desire is not always a medical problem—and it is not automatically HSDD
Lower desire can be a normal response to a demanding season, illness, a new baby, bereavement, changing relationships, aging, or many other circumstances. Frequency of desire is not, on its own, a measure of health.
A more useful question is: Is this change persistent, unwanted, and personally distressing? Distress matters because a person can have infrequent or responsive desire and feel content with it. Conversely, a sustained change that feels upsetting or affects wellbeing may deserve a conversation with a clinician.
Responsive desire is a valid pattern
For many people, desire does not always begin as an urge out of nowhere. It may arise after emotional connection, affectionate contact, stimulation, or a sense of safety and time. This does not need to be “corrected” unless it is distressing, accompanied by another concern such as pain, or no longer works for the person involved. The female sexual response cycle, including responsive desire and variation, can help explain why desire does not always precede intimacy.
HSDD is a clinician-assessed context, not a self-diagnosis
HSDD refers to persistent low sexual desire accompanied by personal distress. A clinician assessing low desire should consider overlapping concerns involving arousal, orgasm, pain, medicines, substances, physical health, and psychological or interpersonal circumstances. It is not a diagnosis made from a hormone value, a single questionnaire result, or a comparison with someone else’s desire.
Low desire: signal, not verdict
Testosterone is one possible biological data point, not an explanation that stands apart from the rest of a person’s life. This assessment map shows what common signals can—and cannot—tell you.
| Finding or question | What it may suggest | What it cannot establish | Useful next conversation |
|---|---|---|---|
| Lower desire without distress | Normal variation, responsive desire, or a situational change may be present. | That a disorder or hormone treatment is needed. | Whether the pattern feels acceptable and whether pain, pressure, or a recent change is involved. |
| Persistent desire loss with distress | A sexual-health assessment may be worthwhile. | That testosterone is the cause or best treatment. | Timeline, life stage, sexual pain, medicines, sleep, health, mood, and context. |
| A low-range testosterone result | One clinical measurement that may be relevant if treatment is being considered. | HSDD, a female androgen-deficiency syndrome, or the cause of low desire. | Test limitations and the broader pattern of symptoms and circumstances. |
| A normal testosterone result | One result within the limits of available testing. | That desire concerns are unimportant or unrelated to health and context. | Pain, dryness, medication timing, stress, mood, fatigue, and relationship factors. |
| Menopause symptoms with dryness or painful sex | Genitourinary symptoms may be reducing interest through discomfort or avoidance. | That testosterone is the primary issue. | Assessment of vaginal and pelvic symptoms and menopause care options. |
| A recent medication change | A possible timing-related contributor. | That the medicine is definitely responsible. | Medication review with the prescribing clinician; do not stop medicines abruptly. |
| High stress, poor sleep, depression, or anxiety | Factors that can affect desire and sexual response. | That symptoms are “all in your head” or that hormones cannot also be relevant. | Support for sleep, mental health, stress, and physical contributors. |
| Relationship pressure, conflict, or disconnection | Interpersonal conditions that can affect desire, comfort, and safety. | That either partner is at fault or that a hormone will solve the issue. | Communication, expectations, consent, connection, and appropriate support. |
Why a testosterone blood test cannot explain low libido on its own
It is understandable to want a clear laboratory answer. But no testosterone cutoff diagnoses HSDD or proves that a person’s low desire is caused by testosterone. The International Society for the Study of Women’s Sexual Health guideline states that total testosterone should not be used to diagnose HSDD.
Why testing is limited in the female range
Testosterone concentrations in women are relatively low, and measurement can be technically challenging. The international consensus statement notes that direct assays of total and free testosterone are highly unreliable in the female range. “Free” and “total” testosterone can add more numbers, but they do not turn a complex concern into a definitive answer.
Clinicians may use testing differently when testosterone treatment is being considered or monitored—for example, to help avoid levels above the physiologic range. That is distinct from using a test as a diagnostic verdict about libido, identity, relationship concerns, or the source of distress.
Menopause, dryness and painful sex: related issues, but not the same issue
Menopause can coincide with changes in desire, but menopause-associated sexual changes are not simply an androgen problem; falling estrogen also affects vaginal tissue and lubrication (see does estrogen affect libido in women?). Vaginal dryness and other genitourinary symptoms can make sex uncomfortable or painful. Anticipating pain may understandably reduce interest or lead to avoidance. More detail is available in this guide to painful sex after menopause.
The American College of Obstetricians and Gynecologists’ information on painful sex notes that menopausal vaginal dryness can contribute to pain. These symptoms warrant their own assessment rather than being folded into a generic “low testosterone” explanation. Sleep disruption, hot flushes, mood changes, body changes, health conditions, and relationship circumstances can matter during this life stage too.
A sudden change after surgical menopause also deserves individualized assessment. A rapid hormonal transition may be relevant, but it does not remove the need to consider pain, recovery, medicines, mood, and the person’s wider circumstances.
Who may benefit from testosterone therapy for low desire?
The best-supported group is postmenopausal women with persistent low sexual desire that causes distress after a broader assessment has considered other contributors. The Global Consensus Position Statement concludes that HSDD is the only evidence-based indication for testosterone therapy in women.
For menopause-associated low desire, NICE menopause guidance recommends considering testosterone supplementation only when hormone replacement therapy alone has not been effective. This is not the same as treating a lab number or prescribing testosterone to anyone who reports less desire.
Testosterone therapy for women: safety and U.S. regulatory context
In the United States, there is currently no FDA-approved testosterone product specifically indicated for women. The FDA’s testosterone information states that its approved testosterone products are approved for men with low testosterone linked to a medical condition. Use in women is therefore off-label and requires individualized clinical judgment.
Formulations are not interchangeable
The trial evidence primarily reflects physiologic-dose systemic, non-oral treatment, often described as transdermal. That evidence should not be assumed to apply to pellets, injections, oral products, or compounded preparations. Specialist guidance does not treat compounded products as equivalent to studied approaches because efficacy and safety data are lacking.
This is not a reason to self-treat with products intended for men or to seek a formulation based on marketing claims. Testosterone therapy, when considered, needs clinical assessment and follow-up.
Known effects and unanswered long-term questions
In trial evidence, testosterone was associated with a higher likelihood of androgenic effects such as acne and increased facial or body hair. The meta-analysis found that oral testosterone adversely affected lipid measures, while non-oral formulations did not show those lipid changes in the analyzed data.
Long-term cardiovascular and breast-safety questions remain unresolved. Available trials were not designed or long enough to settle these outcomes confidently. This uncertainty is one reason treatment decisions should weigh possible modest benefits against potential adverse effects and the individual’s health context.
Other common reasons libido can change besides testosterone
Desire is biopsychosocial: biology, emotions, lived experience, relationships, health, and circumstances interact. The following are not competing explanations; more than one may be relevant at once.
- Medicines: SSRIs, hormonal contraception, and some cardiovascular medicines can affect sexual desire or response. A timing pattern is worth discussing with the prescriber, without changing medicines on your own.
- Stress, burnout, and poor sleep: Fatigue and cognitive overload can leave little capacity for desire or intimacy. Stress can affect low libido through several interacting pathways.
- Depression and anxiety: Both mental health symptoms and some treatments can affect sexual function; see can depression cause low libido in women?
- Physical health and fatigue: Chronic illness, discomfort, and reduced energy can influence sexual interest.
- Relationship context: Conflict, unequal burdens, pressure, poor communication, mismatched desire, or emotional disconnection can affect desire.
- Pain and pelvic-floor concerns: Pain, tension, dryness, and fear of discomfort can alter sexual response.
- Body image, shame, and past experiences: Feeling unsafe, self-conscious, or disconnected from one’s body can matter.
The ACOG overview of sexual health discusses many of these physical, psychological, medication-related, and interpersonal contributors.
When to seek professional support
Not every change in desire requires medical care. It can be useful to speak with a qualified clinician when low desire is persistent and distressing, affects wellbeing or relationships, or began after a medicine or health change.
Seek timely assessment for new or severe sexual pain, vaginal bleeding, pelvic symptoms, or marked dryness. These concerns should not be assumed to be a libido or testosterone issue.
For an appointment, it may help to bring a simple timeline: when the change began; whether it is constant or context-dependent; menopause or menstrual changes; pain or dryness; sleep and mood; health changes; medicines and substances; and the situations in which desire feels more or less possible. This creates a more useful starting point than a single hormone result alone.
Bottom line: a useful hormone question needs a whole-person answer
Does testosterone increase libido in women? For some postmenopausal women with distressing low desire or HSDD, it may offer a modest average benefit. It is not a universal solution, and a testosterone blood test cannot diagnose the cause of low desire.
The most useful assessment looks beyond one hormone: personal distress, life stage, pain or dryness, medications, sleep, stress, mood, health, and relationship context may be equally or more important. Testosterone is one biological influence within sexual wellbeing—not a single switch that explains it all.
Frequently asked questions
Does testosterone cream increase libido in women?
The trial evidence mainly involves physiologic-dose, non-oral testosterone in postmenopausal women with distressing low desire, where the average benefit was modest. In the United States no testosterone product is approved for women, so any use is off-label and needs clinical supervision. Products made for men and compounded preparations are not equivalent to the studied treatments.
What are the side effects of testosterone for women?
In trials, testosterone was associated with more acne and increased facial or body hair. Oral testosterone adversely affected cholesterol measures, while non-oral forms did not in the analyzed data. Long-term breast and cardiovascular safety is not yet established.
Can premenopausal women use testosterone for low libido?
The 2019 global consensus statement found the evidence insufficient to recommend testosterone for sexual function in premenopausal women. Low desire before menopause deserves a broader assessment of health, medicines, mood, pain and context.
Explore related articles in our Anatomy & Hormones topic page.
Educational information only: this article cannot determine the cause of low desire or whether hormone treatment is appropriate for an individual.
